• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers tout use of closed-loop insulin delivery system

October 3, 2018 By Sarah Faulkner

JDRF - updated logoAt this year’s meeting of the European Association for the Study of Diabetes, researchers reported that use of a hybrid day-night closed-loop insulin delivery system is better than sensor-augmented pump therapy for blood sugar control in people with poorly controlled Type 1 diabetes.

The JDRF-funded study included 44 men and 42 women with Type 1 diabetes and randomly assigned them to receive treatment with an insulin pump and a continuous glucose monitor or a closed-loop insulin delivery system.

Participants who used the insulin pump and a continuous glucose monitoring sensor were responsible for making insulin-dosing decisions. But closed-loop insulin delivery systems are designed to integrate the data collected by CGMs directly with an insulin pump, automating insulin delivery using an algorithm.

Over the 12 weeks of the study, people in the closed-loop group spent significantly more time in the target blood sugar range compared to those in the control group. The researchers also noted that participants in the closed-loop group had significant reductions in HbA1c levels compared to the control group.

The time that participants spent with very low blood sugar levels (hypoglycemia) was a median of 12 minutes lower in the closed-loop group and the time spent with very high blood sugar levels (hyperglycemia) was a median of 2 hours and 24 minutes lower in the closed-loop group, according to the researchers.

The study also found that the proportion of time spent in dangerous conditions overall fell from 3.5% at baseline to 2.6% after the study in the closed-loop group. Meanwhile, in the sensor-augmented pump group, this value rose from 3.3% at baseline to 3.9% after the study.

“The use of day-and-night hybrid closed-loop insulin delivery improves glycaemic control while reducing the risk of hypoglycemia in adults, adolescents and children with Type 1 diabetes compared to conventional pump therapy or sensor-augmented pump therapy. Results from our study together with those from previous studies support the adoption of closed-loop technology in clinical practice across all age groups,” the researchers wrote in The Lancet.

“Dr. Hovorka’s study is significant in that it adds to the ever-growing body of evidence showing that closed-loop insulin delivery systems improve outcomes and reduce burden for people with Type 1 diabetes,” Daniel Finan, research director at JDRF, added. “In particular, this study demonstrates that people with diabetes who have sub-optimal control can benefit greatly from such technology.”

“These are great results. I congratulate Professor Hovorka on the vital work he is doing. Type 1 diabetes is a challenging condition, but these results take us a step closer to changing the lives of the millions of people that live with the condition across the world,” Rachel Connor, director of research partnerships at JDRF, said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS